Shuo Wang, Min Zhao, Zihan Su, Dan Yang, Runqing Mu
{"title":"脂肪肝患者 8 种血清肝酶和 3 种无创检测的年度生物变异和个性化参考区间。","authors":"Shuo Wang, Min Zhao, Zihan Su, Dan Yang, Runqing Mu","doi":"10.1016/j.cca.2025.120156","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The liver function tests and noninvasive tests (NITs) play important roles in the follow-up and monitoring of fatty liver disease (FLD). Our aim is to establish annual biological variation (BV) and personalized reference intervals (prRIs) of liver function tests for the first time in order to accurately assess the status and progress of FLD.</p><p><strong>Methods: </strong>67 fatty liver patients who participated in regular physical examination once a year for six consecutive years, were enrolled. Based on these patients, we calculated annual BV and derived parameters, including reference change value (RCV), index of individuality (II), and total variation around the true homeostatic set point (TV<sub>set</sub>) which could further be used to derive prRI.</p><p><strong>Results: </strong>We calculated the annual within-subject BV (CV<sub>I</sub>), within-person BV (CV<sub>P</sub>), RCV, II, TV<sub>set</sub> of 8 liver function tests and 3 NITs for fatty liver patients. CV<sub>I</sub> estimates of fatty liver patients for half of liver function tests were significantly lower than those of healthy people and these could lead to a lower RCV. IIs of all measurands were < 1.4 except for total bile acids (TBA). The mean of CV<sub>P</sub> is similar to the CV<sub>I</sub>; however, there is a significant heterogeneity in CV<sub>P</sub> among different subjects. Annual TV<sub>set</sub> estimates for 7 measurands were lower and prRI was also narrower in fatty liver patients than that of healthy people.</p><p><strong>Conclusion: </strong>Annual BV and their derived parameters based on fatty liver patients can provide an objective basis for the monitoring and follow-up of FLD, a global epidemic disease.</p>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":" ","pages":"120156"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Annual biological variation and personalized reference intervals of 8 serum liver enzymes and 3 noninvasive tests in fatty liver patients.\",\"authors\":\"Shuo Wang, Min Zhao, Zihan Su, Dan Yang, Runqing Mu\",\"doi\":\"10.1016/j.cca.2025.120156\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The liver function tests and noninvasive tests (NITs) play important roles in the follow-up and monitoring of fatty liver disease (FLD). Our aim is to establish annual biological variation (BV) and personalized reference intervals (prRIs) of liver function tests for the first time in order to accurately assess the status and progress of FLD.</p><p><strong>Methods: </strong>67 fatty liver patients who participated in regular physical examination once a year for six consecutive years, were enrolled. Based on these patients, we calculated annual BV and derived parameters, including reference change value (RCV), index of individuality (II), and total variation around the true homeostatic set point (TV<sub>set</sub>) which could further be used to derive prRI.</p><p><strong>Results: </strong>We calculated the annual within-subject BV (CV<sub>I</sub>), within-person BV (CV<sub>P</sub>), RCV, II, TV<sub>set</sub> of 8 liver function tests and 3 NITs for fatty liver patients. CV<sub>I</sub> estimates of fatty liver patients for half of liver function tests were significantly lower than those of healthy people and these could lead to a lower RCV. IIs of all measurands were < 1.4 except for total bile acids (TBA). The mean of CV<sub>P</sub> is similar to the CV<sub>I</sub>; however, there is a significant heterogeneity in CV<sub>P</sub> among different subjects. Annual TV<sub>set</sub> estimates for 7 measurands were lower and prRI was also narrower in fatty liver patients than that of healthy people.</p><p><strong>Conclusion: </strong>Annual BV and their derived parameters based on fatty liver patients can provide an objective basis for the monitoring and follow-up of FLD, a global epidemic disease.</p>\",\"PeriodicalId\":10205,\"journal\":{\"name\":\"Clinica Chimica Acta\",\"volume\":\" \",\"pages\":\"120156\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-01-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinica Chimica Acta\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cca.2025.120156\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cca.2025.120156","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
Annual biological variation and personalized reference intervals of 8 serum liver enzymes and 3 noninvasive tests in fatty liver patients.
Background: The liver function tests and noninvasive tests (NITs) play important roles in the follow-up and monitoring of fatty liver disease (FLD). Our aim is to establish annual biological variation (BV) and personalized reference intervals (prRIs) of liver function tests for the first time in order to accurately assess the status and progress of FLD.
Methods: 67 fatty liver patients who participated in regular physical examination once a year for six consecutive years, were enrolled. Based on these patients, we calculated annual BV and derived parameters, including reference change value (RCV), index of individuality (II), and total variation around the true homeostatic set point (TVset) which could further be used to derive prRI.
Results: We calculated the annual within-subject BV (CVI), within-person BV (CVP), RCV, II, TVset of 8 liver function tests and 3 NITs for fatty liver patients. CVI estimates of fatty liver patients for half of liver function tests were significantly lower than those of healthy people and these could lead to a lower RCV. IIs of all measurands were < 1.4 except for total bile acids (TBA). The mean of CVP is similar to the CVI; however, there is a significant heterogeneity in CVP among different subjects. Annual TVset estimates for 7 measurands were lower and prRI was also narrower in fatty liver patients than that of healthy people.
Conclusion: Annual BV and their derived parameters based on fatty liver patients can provide an objective basis for the monitoring and follow-up of FLD, a global epidemic disease.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.